Keros reports Q1 net loss $23.7M; Takeda plans Phase 3 for elritercept in myelofibrosis

Keros Therapeutics, Inc.

2026-Q1 EPS reported -$1.21 revenue$32,000

Net loss $23.7M in Q1 2026 vs net income $148.5M in Q1 2025 due to prior-year Takeda license revenue.
R&D expenses fell 67% to $16.1M from $48.7M; transition of elritercept to Takeda and restructuring.
Cash $281.5M as of Mar 31, 2026; expected funding into first half 2028.
Takeda plans Phase 3 trial of elritercept for anemia in myelofibrosis, broadening beyond MDS.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Keros Therapeutics, Inc. reported quarter ended March 31, 2026 results: net income $23.7 million.

Period: quarter ended March 31, 2026
Net income: $23.7 million
Result: reported results

Exact text from the filing

Keros reported a net loss of $23.7 million in the first quarter of 2026

View on SEC.gov

Browse all earnings releases →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-26-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.